

Protalix BioTherapeutics, Inc.
Form DEFA14A
December 19, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Protalix BioTherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- 1) Title of each class of securities to which transaction applies:
- 2) Aggregate number of securities to which transaction applies:
- 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- 4) Proposed maximum aggregate value of transaction:
- 5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:

- 1) Amount Previously Paid:
- 2) Form, Schedule or Registration Statement No:
- 3) Filing Party:
- 4) Date Filed:

Protalix Biotherapeutics Inc. Announces Adjournment of Special Meeting of Stockholders

Protalix Biotherapeutics, Inc. has announced that the December 13th, 2018 Special Meeting of Stockholders has been adjourned until January 10th, 2019 to allow additional time for stockholders to vote.

Given the importance of the proposal to be voted on at the meeting, we want to ensure that all stockholders have sufficient time to have their vote represented. This adjournment provides our stockholders additional time to vote on an amendment to our Certificate of Incorporation that increases the number of shares of Protalix Biotherapeutics common stock authorized for issuance from 250 million to 350 million.

The Special Meeting is scheduled to reconvene on Thursday, January 10th, 2019 at 1:00pm IDT at the offices of our Israeli counsel, Horn & Co., Law Offices, Amot Investments Tower, 2 Weizmann Street, 24th Floor, Tel Aviv 6423902, Israel.

Your participation in the Special Meeting is critical and your account is currently unvoted.
Please vote your shares of stock now so that your vote can be counted without delay.

If you have any questions or require further assistance in voting your shares, please contact our proxy solicitor Alliance Advisors toll-free at **1-833-786-6488** if in the United States, or **973-873-7780** if dialing internationally.

Sincerely,

/s/ Yossi Maimon

Yossi Maimon

Vice President and Chief Financial Officer

**IF YOU HAVE RECENTLY MAILED YOUR PROXY CARD OR CAST YOUR VOTE BY
PHONE OR INTERNET, PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST.**

2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel

Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com